Earnings Call Summary | Avanos Medical(AVNS.US) Q4 2023 Earnings Conference
Earnings Call Summary | Avanos Medical(AVNS.US) Q4 2023 Earnings Conference
The following is a summary of the Avanos Medical, Inc. (AVNS) Q4 2023 Earnings Call Transcript:
以下是阿瓦诺斯医疗公司（AVNS）2023年第四季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
Avanos Medical reported Q4 net sales of $173.3 million and full-year sales of $673 million.
The company's gross margin was 58.6% for the quarter and 59.1% for the full year.
SG&A expenses represented 38.9% of revenue for Q4.
Full-year, adjusted EBITDA was $99 million, representing an improvement to 14.7% compared to 13.3% in 2022.
Earnings per share were $0.36 for Q4 and $1.03 for the year.
As of year-end, Avanos had $88 million cash on hand and $168 million of debt outstanding.
The company repurchased $15 million worth of shares in the second half of 2023.
Avanos Medical报告称，第四季度净销售额为1.733亿美元，全年销售额为6.73亿美元。
该公司本季度的毛利率为58.6％，全年毛利率为59.1％。
销售和收购费用占第四季度收入的38.9％。
全年调整后的息税折旧摊销前利润为9900万美元，与2022年的13.3％相比增长了14.7％。
第四季度每股收益为0.36美元，全年每股收益为1.03美元。
截至年底，Avanos手头有8,800万美元的现金和1.68亿美元的未偿债务。
该公司在2023年下半年回购了价值1500万美元的股票。
Business Progress:
业务进展：
The company successfully reduced backorders to less than $2 million by the end of 2023.
Avanos Medical is progressing with its transformation priorities, including strategic and commercial optimization, portfolio transformation, operational profitability enhancement, and ROIC improvement.
Future growth is anticipated from the digestive health portfolio, with expectations of mid to high single-digit organic growth.
The company plans to focus on digestion health and pain management, business process efficiency, cost management, and capital allocation for investment return in 2024.
Revenue for 2024 is projected to be between $685 million and $705 million, with an organic revenue goal of $750 million by 2025. The company aims for a gross margin between 59.5% and 60.5% and an EPS between $1.30 and $1.45 for 2024.
Avanos Medical aims to reduce SG&A expenses to between 41% and 42% of revenue in 2024 and expects to generate free cash flow of about $100 million in 2025.
The company expects steady mid-single-digit organic growth for 2024 and 2025.
到2023年底，该公司成功将缺货订单减少到200万美元以下。
Avanos Medical 正在推进其转型优先事项，包括战略和商业优化、投资组合转型、提高运营盈利能力和改善投资回报率。
消化系统健康产品组合有望实现未来增长，预计将实现中到较高的个位数有机增长。
该公司计划在2024年将重点放在消化健康和疼痛管理、业务流程效率、成本管理和资本配置上，以实现投资回报。
预计2024年的收入将在6.85亿美元至7.05亿美元之间，到2025年的有机收入目标为7.5亿美元。该公司的目标是2024年的毛利率在59.5％至60.5％之间，每股收益在1.30美元至1.45美元之间。
Avanos Medical的目标是在2024年将销售和收购支出减少到收入的41％至42％之间，并预计到2025年将产生约1亿美元的自由现金流。
该公司预计，2024年和2025年将实现稳定的中等个位数有机增长。
More details: Avanos Medical IR
更多详情： Avanos Medical IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。无法完全保证内容的准确性。欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。